SeaStar Medical Holding Corporation (ICU) Q3 Revenue Rose 247% to $0.6M

SeaStar Medical (ICU) reported Q3 2026 revenue of $0.6M, up 247% YoY. Net loss increased to $4.5M from $3.5M, with $4.0M cash on hand. The company is in early commercial stage, growing QUELIMMUNE sales and advancing a pivotal trial.

Original reporting
Published Nov 11, 2026, 9:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 11, 2026, 9:12 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
SeaStar Medical Holding Corporation (ICU) Q3 Revenue Rose 247% to $0.6M — source image
Decision brief

The 30-second read

$ICUBearishMed
01

Why it matters

The numbers provide fresh data for traders assessing short‑term price moves; the trial outcome could be a catalyst.

02

Market read

First‑time earnings disclosure for a micro‑cap; modest trading relevance.

03

What to watch

Potential impact of the pending NEUTRALIZE‑AKI trial results on future valuation.

Relevance 6/10Novelty 6/10Timing: pre‑market today

Background

SeaStar Medical Holding Corp released its Q3 2026 earnings, showing a dramatic revenue increase but deeper losses.

Company-level read

Ticker impact

$ICUBearishMedium confidence
Context

Q3 2026 revenue rose 247% to $0.6M and net loss widened, providing the first public disclosure of the company's quarterly results.

Expected impact

potential modest upside as investors price the revenue growth, tempered by concerns over expanding losses

Evidence & confidence

Revenue growth is significant for a micro‑cap, yet the loss expansion suggests cash burn remains a risk.

Market effects

Highlights growth potential in niche medical device segment but underscores profitability challenges.

Limited to U.S. micro‑cap investors; no broader regional effect.

Minimal global relevance beyond niche biotech interest.

Counterpoint

The revenue surge may be unsustainable; focus on cash burn and upcoming trial results.

Key entities

  • SeaStar Medical Holding Corp

    Micro‑cap medical device firm reporting Q3 results.

Related articles

$ICUHigh

SeaStar Medical Reports Third Quarter 2026 Financial Results and Provides Business Updates

SeaStar Medical Holding Corp (ICU) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SeaStar Medical Reports Third Quarter 2026 Financial Results and Provides Business Updates Continued adoption of the QUELIMMUNE ® therapy yielded 247% increase in net revenue compared to the third quarter of 2025 Achieved nearly 75% enrollment in the NEUTRALIZE-AKI p